| UBQLN3 |
|---|
| Symbol | UBQLN3 |
|---|
| Full Name | Ubiquilin 3 |
|---|
| Chromosome | Xp11.23 |
|---|
| NCBI Gene ID | [50628](https://www.ncbi.nlm.nih.gov/gene/50628) |
|---|
| OMIM | [301052](https://www.omim.org/entry/301052) |
|---|
| Ensembl | [ENSG00000166394](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000166394) |
|---|
| UniProt | [Q9H7D9](https://www.uniprot.org/uniprot/Q9H7D9) |
|---|
| Associated Diseases | [Amyotrophic lateral sclerosis](/diseases/als), [Frontotemporal dementia](/diseases/frontotemporal-dementia), [Parkinson's disease](/diseases/parkinsons-disease) |
|---|
UBQLN3 (Ubiquilin 3) is a member of the ubiquilin family of proteins that play critical roles in protein quality control. Originally identified as a protein involved in cellular proteostasis, UBQLN3 shares structural and functional features with other ubiquilins (UBQLN1, UBQLN2) and has been implicated in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) pathogenesis fecto2011.
The ubiquilin family serves as molecular shuttles that deliver ubiquitinated proteins to the proteasome for degradation, bridging the gap between protein aggregation and clearance pathways chang2015. While UBQLN3 is less studied than its counterparts, it represents an important component of the protein quality control network in neurons.
¶ Gene and Protein Structure
The UBQLN3 gene is located on chromosome Xp11.23 and encodes a protein of 642 amino acids with a molecular weight of approximately 71 kDa. The gene structure consists of multiple exons that encode the characteristic ubiquilin protein domains.
¶ Protein Domains
The UBQLN3 protein contains the hallmark domains of the ubiquilin family ko2017:
-
N-terminal ubiquitin-like (Ubl) domain: The Ubl domain (approximately 80 amino acids) shares ~30% identity with ubiquitin. This domain can bind to the proteasome and may function in targeting ubiquitinated substrates for degradation.
-
Sti1/Hop domain: The central region contains multiple tetratricopeptide repeat (TPR) motifs that mediate protein-protein interactions. This domain allows ubiquilins to interact with various client proteins and chaperones.
-
C-terminal ubiquitin-associated (UBA) domain: The UBA domain (~45 amino acids) binds to ubiquitin chains, enabling recognition of ubiquitinated substrate proteins. This domain allows ubiquilins to recognize proteins tagged for proteasomal degradation.
UBQLN3 participates in protein quality control networks through interactions with:
| Partner |
Interaction |
Function |
| Proteasome |
Ubl domain binding |
Substrate delivery |
| Ubiquitinated proteins |
UBA domain binding |
Cargo recognition |
| Hsp70/Hsp90 |
TPR domain |
Chaperone interaction |
| UBQLN2 |
Homologous |
Potential complex formation |
| TDP-43 |
Indirect |
ALS pathology interaction |
UBQLN3 functions as a molecular adaptor that delivers ubiquitinated proteins to the proteasome matsumoto2013:
flowchart TD
A["Misfolded/Poly-Ubiquitinated Protein"] --> B["UBQLN3 UBA Domain"]
B --> C["UBQLN3 Ubl Domain"]
C --> D["Proteasome 19S Regulatory Particle"]
D --> E["Substrate Unfolding"]
E --> F["Proteasome 20S Core"]
F --> G["Protein Degradation"]
H["Chaperones"] --> A
I["Aggregation"] -->|"Inhibited"| A
The pathway operates as follows:
- Substrate recognition: UBQLN3 binds to ubiquitinated proteins through its UBA domain
- Delivery: The Ubl domain interacts with the proteasome's regulatory particle
- Transfer: Ubiquitinated substrate is transferred to the proteasome for degradation
- Recycling: UBQLN3 is recycled for additional rounds of substrate delivery
Beyond proteasome-mediated degradation, ubiquilins participate in autophagy pathways kim2019:
- Aggregate clearance: UBQLN3 may help deliver protein aggregates to autophagosomes
- Chaperone-mediated autophagy: May interface with selective autophagy receptors
- Lysosomal delivery: Coordinates with endosomal/lysosomal pathways
UBQLN3 influences protein aggregation in neurons:
- Sequestration: Can bind to aggregation-prone proteins, potentially sequestering them
- Co-aggregation: May co-aggregate with disease proteins in inclusions
- Clearance competition: May compete with autophagy and proteasome pathways
UBQLN3 is implicated in ALS through multiple mechanisms kakihana2021, chen2021:
- UBQLN2 mutations (related family member) cause X-linked ALS/FTD deng2011
- UBQLN3 variants have been identified in some ALS patients gkazi2019
- The UBQLN2-ALS connection strongly implicates ubiquilin dysfunction in disease
ALS is characterized by proteasome dysfunction:
- UBQLN3-mediated proteasome delivery is impaired
- Accumulation of ubiquitinated proteins
- Formation of stress granules and protein inclusions
ALS features TDP-43 proteinopathy:
- UBQLN3 interacts with TDP-43 in inclusions
- May affect TDP-43 aggregation and clearance
- Disrupted proteostasis contributes to pathology
UBQLN3 is linked to FTD rutherford2006:
- UBQLN2 mutations cause ALS/FTD spectrum disease
- UBQLN3 expression is dysregulated in FTD brain
- Interaction with tau pathology in FTD
UBQLN3 may also play a role in Parkinson's disease:
- Alpha-synuclein aggregation involves proteostasis disruption
- UBQLN3 may influence alpha-synuclein clearance
- Lewy bodies contain ubiquitinated proteins
UBQLN3 shows tissue-specific expression:
- Testis: Highest expression (where it was initially discovered)
- Brain: Moderate expression, primarily in neurons
- Heart: Low-moderate expression
- Skeletal muscle: Lower expression
- Other tissues: Variable expression
Within the brain, UBQLN3 is expressed in:
- Neurons: Primary expression in excitatory and inhibitory neurons
- Astrocytes: Lower expression
- Microglia: Minimal expression
- Oligodendrocytes: Variable expression
Modulating UBQLN3 function represents a therapeutic strategy anderson2020, davidson2018:
- Proteasome activators: Enhance proteasome function to compensate for impaired delivery
- Ubiquilin stabilizers: Promote UBQLN3 function
- Considerations: Must avoid excessive proteasome activation
- mTOR inhibitors: Promote autophagy (rapamycin, etc.)
- Direct autophagy inducers: Beclin-1, ATG proteins
- Considerations: Balance autophagy vs. proteasome pathways
- Aggregation inhibitors: Prevent protein aggregate formation
- Chaperone enhancement: Increase Hsp70/Hsp90 activity
- Considerations: Must target specific disease proteins
- Blood-brain barrier: CNS-penetrant drugs needed
- Protein interactions: Targeting specific protein-protein interactions
- Cell type specificity: Neuronal vs. systemic effects
- Disease stage: Intervention timing matters
| Approach |
Status |
Application |
| Proteasome inhibitors |
Approved (cancer) |
Not suitable for neurodegeneration |
| Autophagy inducers |
Preclinical |
Being explored in ALS/PD |
| Chaperone modulators |
Research |
Promising approach |
| Gene therapy |
Research |
Viral vector delivery |
- Ubqln2 knockout mice: Neonatal lethality
- Ubqln1 knockout: Viable with age-related phenotypes
- Conditional knockouts: Tissue-specific effects
- Transgenic models: Disease-relevant phenotypes
- ALS mouse models with UBQLN2 mutations show:
- Progressive motor dysfunction
- Proteasome impairment
- TDP-43 inclusions
- Premature death
- Cellular specificity: How does UBQLN3 function differ from UBQLN1/2?
- Regulation: What controls UBQLN3 expression and activity?
- Therapeutic targeting: How to specifically enhance UBQLN3 function?
- Biomarkers: Are there biomarkers for proteostasis dysfunction?
- Structural studies: Cryo-EM of UBQLN3-substrate complexes
- Small molecule modulators: Drug-like compounds targeting ubiquilins
- Gene therapy: Viral delivery of UBQLN3
- Combination approaches: Multiple proteostasis targets